Abstract: An occlusive medical implant for implantation within a left atrial appendage may include an expandable framework configured to self-expand from a collapsed configuration to an expanded configuration, and an occlusive element disposed on a proximal portion of the expandable framework. At least a portion of the expandable framework may be mechanically expandable from the expanded configuration to a securement configuration. When the occlusive medical implant is disposed within the left atrial appendage, the expandable framework exerts a first radial force on the left atrial appendage in the expanded configuration and the expandable framework exerts a second radial force on the left atrial appendage in the securement configuration. The second radial force is greater than the first radial force.

Abstract: According to one aspect of the disclosure, a delivery device may include a handle, a catheter sheath extending distally from the handle, and a hemostasis valve positioned within the handle. The hemostasis valve may be located proximal to the catheter sheath and distal to a proximal end of the handle. The delivery device may also include a hemostasis bypass assembly coupled to the handle. The hemostasis bypass assembly may include a bypass tube coupled to an actuator. The actuator may be configured to be transitioned between a first condition in which a distal end of the bypass tube is positioned proximal to the hemostasis valve and the hemostasis valve is closed, and a second condition in which the distal end of the bypass tube traverses the hemostasis valve and the hemostasis valve is opened.

Abstract: The present invention relates to a process for the synthesis of organosulfate salts of amino acid esters comprising the steps of reacting at least one lactam with at least 3 carbon atoms in the lactam ring with sulfuric acid in an aqueous solution followed by esterification of the reaction product of the previous step with at least 200 mol-% of at least one alcohol selected from the group consisting of linear alkyl alcohol containing one hydroxy group, branched alkyl alcohol containing one hydroxy group, linear alkylether alcohol containing one hydroxy group, branched alkylether alcohol containing one hydroxy group, phenoxyalkanols containing one hydroxy group, and mixtures thereof; followed optionally removal of water and/or removal of excess alcohol.

Abstract: The present disclosure is directed to a flexible architecture for video gaming applications. In some embodiments, the flexible architecture is platform agnostic and provides a continuous visual experience for players across different platforms while engaging them at different levels of play. The architecture provides user interfaces that facilitate access to video gaming applications in various ways that may include: via social networks or sites; via wall posts or via an online social networking service that enables its users to send and read text-based posts; via mobile devices (iOS, Android, or Windows-based smart phones); or via dedicated game consoles.

Abstract: The subject disclosure relates to techniques for real-time lane validation. A process of the disclosed technologies can include steps for receiving a route from a remote computing system, the route indicating lanes on the route that an autonomous vehicle must traverse, traversing at least one lane of the lanes on the route, and sending sensor data to the remote computing system after traversing the at least one lane, the sensor data indicating whether the at least one lane is in accordance with a virtual lane of a virtual map, the virtual lane corresponding to the at least one lane.

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: A surgical instrument including a reusable and sterilizable hub assembly and a releasably connectable disposable blade assembly allows multiple reuse of the hub assembly in conjunction with single use disposable blade assemblies.

Abstract: A Container For Consumable Liquids Having Chambers For Separating Ingredients And A Mixing Chamber, which is a unitary modular fluid container with a multitude of components, whereby, the segmented contents, such as alcohol, may be combined through an apparatus of mixing.

Abstract: A medical implant including an expandable framework configured to shift between a collapsed configuration and an expanded configuration, the expandable framework comprising a plurality of interconnected struts defining a plurality of cells; and an occlusive element connected to the expandable framework and having an inner surface and an outer surface. The expandable framework may include a plurality of securement members projecting from the plurality of interconnected struts. One of the inner surface or the outer surface of the occlusive element may be in contact with the plurality of interconnected struts, and the other of the inner surface and the outer surface not in contact with the plurality of interconnected struts may lie against an opposing surface of each of the plurality of securement members. A tip portion of the plurality of securement members may not extend radially outward of the plurality of interconnected struts.

Abstract: Fabric treatment compositions that include certain polymer systems, such as systems that include a first polymer that is a soil release polymer and a second polymer that is a graft copolymer (e.g., a PEG/vinyl acetate polymer), an alkoxylated polyalkyleneimine polymer, or a mixture thereof. Related processes and uses.

Abstract: Pyrrolo[2,3-b]pyridine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,3-b]pyridine compound or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

Abstract: A hinged object, such as a door, window, gate, lid, etc., comprises a first hinge, a second hinge, and an electromechanical locking device mounted on or in the hinged object. A first electrical wire is embedded in the hinged object that couples the electromechanical locking device to the first hinge, the first hinge to couple to a low-voltage power source to supply low-voltage electrical current to the electromechanical locking device via the first electrical wire. A second wire is embedded in the hinged object that couples the electromechanical locking device to the second hinge, the second hinge to couple to the low-voltage power supply to return low-voltage electrical current from the electromechanical locking device to the low-voltage power supply via the second electrical wire.

Abstract: The subject disclosure relates techniques for evaluating map quality. In some aspects, a process of the disclosed technology includes steps for receiving change data indicating one or more feature discrepancies associated with one or more geographic regions of a digital map, analyzing the change data to determine which of the one or more feature discrepancies resulted in verified updates to the digital map, and generating a quality score for each of the geographic map regions based on the verified updates. Systems and machine-readable media are also provided.

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Abstract: Liquid detergent compositions can include a first surfactant which is a mixture of surfactant isomers of Formula 1 and surfactants of Formula 2: wherein from about 50% to about 100% by weight of the first surfactant are isomers having m+n=11; wherein between about 25% to about 50% of the mixture of surfactant isomers of Formula 1 have n=0; wherein from about 0.001% to about 25% by weight of the first surfactant are surfactants of Formula 2; and wherein X is a hydrophilic moiety; and a second surfactant including a C12-C15 alkyl ethoxy sulfate with an average degree of ethoxylation of about 1.5 to about 3.

Abstract: Liquid detergent compositions can include a first surfactant which is a mixture of surfactant isomers of Formula 1 and surfactants of Formula 2: wherein from about 50% to about 100% by weight of the first surfactant are isomers having m+n=11; wherein between about 25% to about 50% of the mixture of surfactant isomers of Formula 1 have n=0; wherein from about 0.001% to about 25% by weight of the first surfactant are surfactants of Formula 2; and wherein X is a hydrophilic moiety; and a second surfactant including a linear alkyl benzene sulfonate.

Abstract: Liquid detergent compositions can include a first surfactant which is a mixture of surfactant isomers of Formula 1 and surfactants of Formula 2: wherein from about 50% to about 100% by weight of the first surfactant are isomers having m+n=11; wherein between about 25% to about 50% of the mixture of surfactant isomers of Formula 1 have n=0; wherein from about 0.001% to about 25% by weight of the first surfactant are surfactants of Formula 2; and wherein X is a hydrophilic moiety; and an encapsulate including a shell and a core, wherein the shell includes a polyacrylate and the core includes a perfume.

Abstract: Liquid detergent compositions can include a first surfactant which is a mixture of surfactant isomers of Formula 1 and surfactants of Formula 2: wherein from about 50% to about 100% by weight of the first surfactant are isomers having m+n=11; wherein between about 25% to about 50% of the mixture of surfactant isomers of Formula 1 have n=0; wherein from about 0.001% to about 25% by weight of the first surfactant are surfactants of Formula 2; and wherein X is a hydrophilic moiety; and a second surfactant including a nonionic ethoxylated alcohol.

Abstract: A request to generate a storage system model is received. The storage system model represents at least a portion of a storage system. In response to receiving the request, a storage system interface configuration is loaded. The storage system interface configuration comprises an attribute of an entity model. The attribute corresponds to an attribute of a storage system entity of the storage system. Further in response to receiving the request, the entity model is identified as representing the storage system entity. In response to identifying the entity model as representing the storage system entity, the entity model is instantiated.

Abstract: A substrate processing system includes a showerhead pedestal, a carrier ring, a showerhead, and an RF source. The showerhead pedestal includes a top surface defining a first plurality of through holes configured to output a plasma gas mixture. The carrier ring is arranged on the top surface of the showerhead pedestal to support a substrate at a predetermined distance from the top surface of the showerhead pedestal. The showerhead is arranged above the carrier ring and includes a body defining a plenum, a recessed region located on a substrate-facing surface of the body, and a second plurality of through holes extending from the plenum through the substrate-facing surface of the body in the recessed region to disperse a purge gas onto a top surface of the substrate. The RF source is configured to strike plasma between a bottom surface of the substrate and the top surface of the showerhead pedestal.